Lyell Immunopharma, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-06-30 was 377.01K shares, a 54.73% decline year-over-year.
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-03-31 was 868.83K shares.
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 3.75K shares, a 99.70% decline from fiscal 2024.
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 1.25M shares, a 58.42% decline from fiscal 2023.
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 3.00M shares, a 16.78% decline from fiscal 2022.
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 3.60M shares, a 30.91% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2025-12-31 | 3.75K shares 10-K · filed 2026-03-12 | |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | 1.25M shares 10-K · filed 2025-03-11 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 2.76M shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 377.01K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | 3.41M shares derived: sum of 4 quarters · filed 2024-08-07 |
| 2024-03-31 | 868.83K shares 10-Q · filed 2024-05-06 | 3.87M shares derived: sum of 4 quarters · filed 2024-05-06 |
| 2023-12-31 | 1.52M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | 3.00M shares 10-K · filed 2024-02-28 |
| 2023-09-30 | 645.70K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | 1.57M shares derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | 832.84K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 2.30M shares derived: sum of 4 quarters · filed 2023-08-08 |
| 2023-03-31 | 0.00 shares 10-Q · filed 2023-05-04 | 1.89M shares derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-12-31 | 87.71K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | 3.60M shares 10-K · filed 2023-02-28 |
| 2022-09-30 | 1.37M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 5.49M shares derived: sum of 4 quarters · filed 2022-11-08 |
| 2022-06-30 | 428.46K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | 4.38M shares derived: sum of 4 quarters · filed 2022-08-04 |
| 2022-03-31 | 1.71M shares 10-Q · filed 2022-05-10 | |
| 2021-12-31 | 1.97M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | 2.75M shares 10-K · filed 2022-03-29 |
| 2021-09-30 | 265.58K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |